Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Freenome (FRNM) and Abbott Laboratories (ABT) said Monday that the US Food and Drug Administration approved SimpleScreen CRC, a blood-based colorectal cancer screening test. The c ...

On Jan. 24, Abbott posted its year-end and fourth-quarter numbers for the last three months of 2023. Revenue in Q4 rose by 1.5% year over year to $10.2 billion, but on an organic basis and when ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The North Chicago company said ...

Abbott Laboratories stock rose 8% Wednesday and was the second biggest gainer on the S&P 500 index, after the diagnostics and medical-device company beat earnings estimates for the first quarter. As ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories is rebounding from last year’s manufacturing ...

Shares of Abbott Laboratories popped after the company's earnings and revenue topped Wall Street estimates, defying a dramatic slowdown in sales of its Covid tests. The results were driven in part to ...

Growth-conscious investors appreciate Abbott's commitment to innovation, which has helped make it one of the world's leading providers of next-generation medical devices and diagnostics. However, ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Laboratories’ latest earnings call struck a cautiously upbeat tone, blending steady growth and strong device momentum with clear acknowledgment of near‑term pressures. Management underscored ...